Paul, Weiss

Meggin Bednarczyk

Deals
7
Latest
Jun 2026
Most deals in
Biotech

Firm

Deals by year
Meggin Bednarczyk: deals by year0720252026 YTD: 7 M&A72026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Meggin Bednarczyk was named on, most recent first
Jun 2026 Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program Sangamo TherapeuticsEli Lilly and CompanyAsset saleLegal adviser to Eli Lilly and Company (acquirer)Completed–Biotech+1Eli Lilly and Company acquisition of Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program
Jun 2026 Stephano Slack –Madison Dearborn PartnersStakeLegal adviser to Madison Dearborn Partners (acquirer)Completed–Accounting, legal and consultingMadison Dearborn Partners stake in Stephano Slack
Mar 2026 Ouro Medicines –GileadAcquisitionLegal adviser to GalapagosAnnounced1,675.0Biotech+1Gilead acquisition of Ouro Medicines
Mar 2026 Walbro business First Brands GroupOverdrive CapitalAsset saleLegal adviser to PolarisCompleted50.0Automotive+1Overdrive Capital acquisition of Walbro business
Mar 2026 Boyd Thermal business of Boyd Goldman Sachs Asset ManagementEatonAsset saleLegal adviser to Eaton (acquirer)Completed9,500.0Manufacturing+2Eaton acquisition of Boyd Thermal business of Boyd
Feb 2026 35Pharma –GSKAcquisitionLegal adviser to GSK (acquirer)Announced950.0Biotech+1GSK acquisition of 35Pharma
Feb 2026 Orna Therapeutics –Eli Lilly and CompanyAcquisitionLegal adviser to Eli Lilly and Company (acquirer)Announced2,400.0Biotech+1Eli Lilly and Company acquisition of Orna Therapeutics

Deals where Meggin Bednarczyk is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.